TABLE II.
Association Between Clinical Variables at End of Study and RBC Alloimmunizationa
| Variable | Frequency (%) | P-value | |
|---|---|---|---|
| Genotype | SS | 33/121 (27%) | 0.6 |
| SC | 6/25 (24%) | ||
| Other | 3/19 (16%) | ||
| Gender | Male | 16/72 (22%) | 0.5 |
| Female | 26/94 (28%) | ||
| Indication for Transfusion | Acute Vaso-occlusive Indication | 26/100 (26%) | 0.9 |
| Nonacute Indication | 16/66 (24%) | ||
| TRV≥2.5 (m/s) | Yes | 9/18 (50%) | 0.02 |
| No | 33/148 (22%) | ||
| History of leg ulcers | Yes | 7/16 (43%) | 0.1 |
| No | 35/150 (23%) | ||
| History of AVN | Yes | 14/39 (36%) | 0.09 |
| No | 28/127 (22%) | ||
| History of ACS | Yes | 36/127 (28%) | 0.1 |
| No | 6/39 (15%) | ||
| History of Stroke | Yes | 2/10 (20%) | 0.9 |
| No | 40/156 (25%) | ||
| History of Retinopathy | Yes | 10/25 (40%) | 0.08 |
| No | 32/141 (23%) | ||
| Use of Hydroxyurea | Yes | 20/60 (33.3%) | 0.09 |
| No | 84/106 (79.2%) |
a
Using summary data at the time of the last type and screen on study.
TRV: tricuspid regurgitant jet velocity.